Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
Recruiting
Phase 4
Interventional Study
Staphylococcus Aureus Endocarditis
Staphylococcus Aureus Septicemia
Staphylococcus Aureus Bloodstream Infection
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 300 (estimated)
- Sponsor
- Todd C. Lee MD MPH FIDSA · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention.
Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if c…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
The participant must meet all inclusion and exclusion criteria for the SNAP
Platform (NCT05137119) and also the following inclusion and exclusion criteria:
Inclusion Criteria:
* Patient is taking aspirin for secondary prevention of cardiovascular disease (coronary, cerebrovascular, or peripheral …
Contacts